JPRN-jRCT2080222523未知2 期
A double-blind, placebo-control, randomized, dose-finding phase II/III study to evaluate the efficacy and safety of TAC-202 in patients with chronic idiopathic urticaria
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Subjects with a documented history of chronic urticaria for at least 4 weeks prior to consent acquisition.
排除标准
- •Subjects with any of the following diseases that may hinder efficacy evaluation.
- •Acute eczema/ Chronic eczema/ Contact dermatitis/ Atopic dermatitis/ Nummular eczema/ Autosensitization dermatitis/ Pompholyx eczema/ Asteatotic eczema/ Lichen simplex chronicus/ Acute prurigo/ Subacute prurigo/ Chronic prurigo/ Systemic pruritus/ Regional pururitus/ Vascular edema/ Cholinergic urticarial/ Mechanical urticaria (chill, sunlight, warmth/heat, delayed pressure, water, vibration)/ Aspirin-induced urticarial/ Urticaria associated with vasculitis or collagen disorder/ Urticaria of known origin/ Urticaria related to the thyroid gland/ Urticaria pigmentosa/ Food-dependent motofacient anaphylaxis/ Schnitzler syndrome/ CAPS (cryopyrin associated periodic syndrome)/ Psoriasis/ Ichthyosis
- •Subjects who previously developed anaphylaxis to antihistamine drugs or ingredients in the investigational drug.
研究者
相似试验
尚未招募
2 期
Homoeopathic medicines for eructatioCTRI/2024/06/069356The Calcutta Homoeopathic Medical College and Hospital
进行中（未招募）
1 期
A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations - G2301EUCTR2008-005479-82-NOovartis Pharma Services AG214
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations - G2301EUCTR2008-005479-82-GBovartis Pharma Services AG214
进行中（未招募）
不适用
A study to check how safe, beneficial and tolerable the drug canakinumab is for patients with SJIAEUCTR2008-005479-82-Outside-EU/EEAovartis Pharma Services AG177
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations - G2301EUCTR2008-005479-82-ATovartis Pharma Services AG214